Compare TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock vs Twist Bioscience Corp — how do they compare? TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $244.22 (market cap $46.84B), while Twist Bioscience Corp trades at $124.83 (market cap $7.72B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 6.1× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals.
| TTWO | TWST | |
|---|---|---|
Market Cap | $46.84B | $7.72B |
Sector | Media | Health |
52-Week High | $262.29 | $124.88 |
52-Week Low | $189.69 | $24.16 |
Enterprise Value | $47.96B | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Take-Two Interactive (TTWO) trades at $244.33, down 3.64% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. Recent Q1 2026 earnings beat expectations, driven by NBA 2K and Grand Theft Auto performance, while the company maintains focus on the upcoming GTA VI launch in November 2026. Fundamentals show revenue growth to $5.63B in 2025, but net losses persist, with a negative net income margin of -4.79%.
The stock's upside potential is tied to GTA VI's success, with a consensus price target of $300.55 offering 23% upside. Key risks include execution on the high-stakes game launch, sustained profitability challenges, and competitive pressures in the gaming industry. Investor sentiment remains optimistic due to the blockbuster title's preorder momentum.
Twist Bioscience (TWST) trades at $123.76, down 0.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, with 2025 revenue at $376.57 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights an upsized $300 million public offering and an analyst upgrade, contributing to positive sentiment.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, negative cash flow, and high valuation ratios pose significant risks. Investors should weigh the growth trajectory against the path to profitability and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
